2012 | Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Chemotherapy Followed by High-Dose Therapy with ASCT for Newly Diagnosed Multiple Myeloma; Open-Labeled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis. | 문영철 | Meeting Abstract |
2011 | Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Induction Chemotherapy Followed by High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma; Open-Labelled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis | 문영철 | Meeting Abstract |
2021 | The 2020 revision of the guidelines for the management of myeloproliferative neoplasms | 문영철 | Review |
2016 | The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea | 문영철 | Article |
2007 | The clinical outcomes of autologous stem cell transplantation in peripheral T cell lymphoma: From retrospective Multicenter study in Korea. | 문영철 | Meeting Abstract |
2018 | The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma | 문영철 | Article |
2020 | The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study) | 문영철 | Article |
2007 | The equal activity of azacytidine in 4 risk groups of IPSS in MDS | 문영철 | Meeting Abstract |
2006 | The intention to treat analysis of the different post remission therapy modalities in AML patients with the "Intermediate Risk Group (IPG)" based on cytogenetics. | 성주명; 문영철 | Meeting Abstract |
2009 | The Level of Peroxiredoxin and Catalase On Single Cell Level Is Correlated with the Positivity of Ph Chromosome in the Bone Marrow of CML Patients During Imatinib Therapy. | 성주명; 이서구; 유은선; 허정원; 이경은; 문영철; 남은미; 우현애 | Meeting Abstract |
2006 | The LTB4 receptor is involved not only in the downstream pathway of rhG-CSF mobilization but in the LTB4 mobitization pathway in C57BL/6 mice. | 이순남; 성주명; 유은선; 이경은; 문영철 | Meeting Abstract |
2015 | The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea | 문영철 | Article |
2014 | Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer | 이순남; 성순희; 성주명; 이경은; 문영철; 남은미 | Article |
2015 | Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy | 문영철 | Article |
2010 | VEGFA and VEGFR2 Genetic Polymorphisms and Survival In Patients with Diffuse Large B Cell Lymphoma | 정화순; 문영철 | Meeting Abstract |